Drug Profile


Alternative Names: KRP 197; KRP-197OD; ONO 8025; ONO-8025OD; Staybla; Staybla OD Tablets; Uritos; Uritos OD Tablets

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Kyorin Pharmaceutical
  • Developer Ajanta Pharma; Chong Kun Dang; Eisai Co Ltd; Kyorin Pharmaceutical; Ono Pharmaceutical
  • Class Imidazoles; Small molecules; Urologics
  • Mechanism of Action Muscarinic M1 receptor antagonists; Muscarinic M3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Overactive bladder; Pollakisuria; Urinary incontinence
  • Phase II Chronic obstructive pulmonary disease

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for clinical-Phase-Unknown development in Overactive bladder(Adjunctive treatment, Combination therapy) in Japan (PO, Fast dissolve)
  • 04 Oct 2016 Launched for Overactive bladder in Thailand (PO)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Pollakisuria in United Kingdom (PO, Tablet)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top